@Davisite Very detailed; however the latest 4C shows a quarter...

First 4 Last

Share
Profile

Follow
Wise_One

8,280 Posts.

358

15/12/18

21:54

Post #: 36871779
Share

Originally posted by Davisite ↑

I wouldn't say rudimentary, more limited. The main reason I have posted is to make sure I haven't missed something important so thank for your response.

There are other (or at least were) comptitors in the protein-based blood screening. From the prospectus both Applied Proteomics and VolitionRx are listed as offering protein-based blood screening tests. More worrying Applied Proteomics' test seems to have been a commercial failure [1]. They spent US$50 million and sold off their IP for US$1.85 million in 2018. I haven't been through the entire scientific literature, but I have found quite a few research papers on this approach too.

DNA tests don't have to be more expensive than protein based tests, it all really depends on the test design and the lab. Having said this trying to sell a test on cost in this market is really hard. Even if your competitors are more expensive they have a habit of dropping their prices if they know they have deeper pockets - the diagnostic market is a cut-throat industry with some very big players who don't mind playing dirty.

We can agree to disagree on the need for a CR in 2019, but when you are spending $2 million a quarter and have $5 million in the bank and are about to go into a clinical testing program (Study 7) I don't think you have much chance of reaching the end of 2019 without raising more cash.

1. https://www.genomeweb.com/proteomics-protein-research/applied-proteomics-sells-assets-discerndx-185m

Expand

@Davisite

Very detailed; however the latest 4C shows a quarter burn of $793k & cash at end of quarter of $6,968m

This is against your claim of 2m/qtr & only 5m in the bank...

So if you can't even get these elementary figures right which are taken directly off the 4C, how are we to even begin to take the rest of your post seriously?

You may know what you're talking about on the technical side of things, but getting this so very wrong shoots your credibility down in an instant

Just Saying ...

Last edited by Wise_One: 15/12/18

RHY Price at posting: 15.5¢ Sentiment: Buy Disclosure: Held
5 Upvote

1 Great analysis

Reply

Top Stories

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

RSG

Resolute shares bounce back as second payment made to Mali government to secure workers' release

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

There are more pages in this discussion • 11 more messages in this thread...

First 4 Last

Add RHY (ASX) to my watchlist

(20min delay)
Last 9.3¢		Change 0.002(1.65%)		Mkt cap ! $15.41M

Open	High	Low	Value	Volume
9.0¢	9.4¢	9.0¢	$71.56K	768.2K

Buyers (Bids)

No.	Vol.	Price($)
3	157347	9.2¢

Sellers (Offers)

Price($)	Vol.	No.
9.3¢	21660	2

View Market Depth

No.	Vol.	Price($)
2	75525	0.063
1	16000	0.062
2	83639	0.060
2	38605	0.051
1	66665	0.045

Price($)	Vol.	No.
0.064	9245	1
0.065	51999	3
0.066	107305	1
0.067	195346	2
0.070	1794	1

Last trade - 12.33pm 29/11/2024 (20 minute delay)

RHY (ASX) Chart

@Davisite Very detailed; however the latest 4C shows a quarter...

Top Stories

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Resolute shares bounce back as second payment made to Mali government to secure workers' release

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Buyers (Bids)

Sellers (Offers)